Combination Antibody Therapy With Apolizumab (1D10) And Rituximab (CD20) In Relapsed Lymphoma And CLL

Trial Profile

Combination Antibody Therapy With Apolizumab (1D10) And Rituximab (CD20) In Relapsed Lymphoma And CLL

Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 May 2017

At a glance

  • Drugs Apolizumab (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Mar 2017 Status changed from completed to discontinued.
    • 18 Mar 2017 Status changed from completed to discontinued.
    • 29 Sep 2011 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top